UBS AM’s Relmada Therapeutics RLMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$788 Buy
+209
New +$1.02K ﹤0.01% 4148
2022
Q4
– Sell
-22,671
Closed -$839K – 2713
2022
Q3
$839K Buy
22,671
+9,142
+68% +$253K ﹤0.01% 2069
2022
Q2
$257K Sell
13,529
-10,591
-44% -$231K ﹤0.01% 2514
2022
Q1
$651K Buy
+24,120
New +$499K ﹤0.01% 2357
2021
Q3
– Sell
-7,358
Closed -$236K – 2770
2021
Q2
$236K Buy
7,358
+958
+15% +$33.3K ﹤0.01% 2691
2021
Q1
$225K Hold
6,400
– – ﹤0.01% 2543
2020
Q4
$205K Sell
6,400
-5,500
-46% -$189K ﹤0.01% 2495
2020
Q3
$448K Buy
11,900
+6,400
+116% +$247K ﹤0.01% 2188
2020
Q2
$246K Buy
+5,500
New +$233K ﹤0.01% 2337

Other funds holding RLMD

UBS AM's RLMD Position: Q3 2026 in Review

UBS AM opened a new position in Relmada Therapeutics (RLMD) in Q3 2026: 209 shares worth $788. The stake represents ﹤0.01% of the portfolio and ranks #4148 among its holdings. This is a return to the name: UBS AM previously reported a position in RLMD as recently as Q3 2022.

UBS AM first reported a position in RLMD in Q2 2020 and has held it in 9 quarters since. The position peaked at $839K in Q3 2022. 105 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.

  • UBS AM held 209 shares of Relmada Therapeutics worth $788 as of Q3 2026.
  • Relmada Therapeutics was a new UBS AM position in Q3 2026.
  • Relmada Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4148 holding.
  • UBS AM first reported a position in Relmada Therapeutics in Q2 2020 and has held it in 9 quarters since.
  • UBS AM's Relmada Therapeutics position peaked at $839K in Q3 2022.
  • 105 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.